Antibiotic market to reach US$ 74.07 billion by 2033; FDA approves GSK’s Blujepa for uncomplicated UTIs

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Mometasone Furoate Monohydrate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

96 API Suppliers, 36 USDMF, 29 CEP/COS, 9 JDMF, 19 EU WC, 9 KDMF, 34 NDC API, 50 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

138 Drugs in Development

138 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

405 FDF Dossiers, 41 FDA Orange Book, 202 Europe, 22 Canada, 69 Australia, 31 South Africa, 40 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;TOPICAL - 0.1%, CREAM;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, LOTION;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, AEROSOL, METERED;INHALATION - 0.05MG/INH, AEROSOL, METERED;INHALATION - 0.10MG/INH, AEROSOL, METERED;INHALATION - 0.20MG/INH, SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, POWDER;INHALATION - 0.11MG/INH, POWDER;INHALATION - 0.22MG/INH, AEROSOL, METERED;INHALATION - 0.005MG/INH;0.05MG/INH, AEROSOL, METERED;INHALATION - 0.005MG/INH;0.1MG/INH, AEROSOL, METERED;INHALATION - 0.005MG/INH;0.2MG/INH

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Rochem International Inc, 1 SPI Pharma, 5 DKSH, 2 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 6 Kirsch Pharma, 6 Actylis, 1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 4 BASF, 1 CD Formulation, 3 DFE Pharma, 2 Finar, 7 Gangwal Chemicals, 1 Ideal Cures, 5 Kerry, 2 Keval Exports, 1 Kima Chemical, 6 Microlex e.U, 1 Nanjing Bold Chemical, 1 Nitika Pharmaceutical Specialities, 1 Pharmatrans-Sanaq, 1 Pluviaendo, 1 Prachin Chemical, 9 Roquette, 6 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Sigachi Industries, 1 Silverline Chemicals, 1 The Dow Chemical Company, 1 Valens Pharmachem, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

21 Solubilizers, 20 Thickeners and Stabilizers, 17 Parenteral, 16 Fillers, Diluents & Binders, 16 Direct Compression, 11 Topical, 9 Coating Systems & Additives, 9 Film Formers & Plasticizers, 9 Granulation, 8 Co-Processed Excipients, 6 Rheology Modifiers, 5 Disintegrants & Superdisintegrants, 5 Emulsifying Agents, 4 Taste Masking, 3 Controlled & Modified Release, 3 Chewable & Orodispersible Aids, 3 Surfactant & Foaming Agents, 2 Lubricants & Glidants, 2 Coloring Agents, 1 API Stability Enhancers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 50 News #PharmaBuzz

GLOBAL SALES INFORMATION

14 US Medicaid Prescriptions, 57 Regulatory FDF Prices, 16 Annual Reports

MARKET PLACE

17 APIs, 4 FDF Dossiers

PATENTS & EXCLUSIVITIES

23 US Patents, 1 US Exclusivities, 34 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/11/2025	Symbiotec Pharmalab	India	SYMBIOTEC PHARMALAB PRIVATE LIMITED Indore IN	CEP 2007-194 - Rev 04	Mometasone furoate, Micronised	2025-06-02	Valid	Chemical		1449
29/11/2025	Coral Drugs Private Limited	India	CORAL DRUGS PRIVATE LIMITED New Delhi IN	R0-CEP 2022-081 - Rev 00	Mometasone furoate	2023-05-26	Valid	Chemical		1449

Mometasone Furoate Monohydrate

Mometasone Furoate Monohydrate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

96 API Suppliers

36 USDMF

29 CEP/COS

9 JDMF

19 EU WC

9 KDMF

34 NDC API

50 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

138 Drugs in Development

INTERMEDIATES

3 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

405 FDF Dossiers

41 FDA Orange Book

202 Europe

22 Canada

69 Australia

31 South Africa

40 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

OINTMENT;TOPICAL - 0.1%

CREAM;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

LOTION;TOPICAL - 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

AEROSOL, METERED;INHALATION - 0.05MG/INH

AEROSOL, METERED;INHALATION - 0.10MG/INH

AEROSOL, METERED;INHALATION - 0.20MG/INH

SPRAY, METERED;NASAL - 0.05MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

POWDER;INHALATION - 0.11MG/INH

POWDER;INHALATION - 0.22MG/INH

AEROSOL, METERED;INHALATION - 0.005MG/INH;0.05MG/INH

AEROSOL, METERED;INHALATION - 0.005MG/INH;0.1MG/INH

AEROSOL, METERED;INHALATION - 0.005MG/INH;0.2MG/INH

RELATED EXCIPIENT COMPANIES

2 EUROAPI

1 Rochem International Inc

1 SPI Pharma

5 DKSH

2 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

6 Kirsch Pharma

6 Actylis

1 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Ashland

4 BASF

1 CD Formulation

3 DFE Pharma

2 Finar

7 Gangwal Chemicals

1 Ideal Cures

5 Kerry

2 Keval Exports

1 Kima Chemical

6 Microlex e.U

1 Nanjing Bold Chemical

1 Nitika Pharmaceutical Specialities

1 Pharmatrans-Sanaq

1 Pluviaendo

1 Prachin Chemical

9 Roquette

6 Seppic

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

8 Sigachi Industries

1 Silverline Chemicals

1 The Dow Chemical Company

1 Valens Pharmachem

1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

21 Solubilizers

20 Thickeners and Stabilizers

17 Parenteral

16 Fillers, Diluents & Binders

CREAM;TOPICAL - 0.1% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

LOTION;TOPICAL - 0.1% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SPRAY, METERED;NASAL - 0.05MG/SPRAY Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons